Opdivo In Combination With Cisplatin-Based Chemotherapy Followed By Opdivo Demonstrates Significant Survival Benefits For Cisplatin-Eligible Patients with Unresectable Or Metastatic Urothelial Carcinoma In Phase 3 CheckMate -901 Trial
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (NYSE:BMY) announced results from the Phase 3 CheckMate -901 trial, where Opdivo in combination with cisplatin-based chemotherapy demonstrated significant improvements in overall survival and progression-free survival for patients with unresectable or metastatic urothelial carcinoma. The treatment reduced the risk of death by 22% and showed a tolerable safety profile. The data will be presented at the European Society for Medical Oncology Congress 2023.
October 17, 2023 | 7:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's successful Phase 3 trial results for Opdivo in combination with chemotherapy could potentially boost its stock in the short term.
The successful trial results for Opdivo, a key product of Bristol Myers Squibb, could potentially lead to increased sales and revenue for the company, thereby positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100